Cholesterol-lowering drug plus chemoimmunotherapy before surgery for advanced colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new treatment combination for people with locally advanced colon cancer that has not spread. It combines a cholesterol-lowering drug (tafolecimab) with standard chemotherapy and immunotherapy before surgery, to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of colon adenocarcinoma that has grown through the bowel wall (T3c stage or higher).
- You must be between 18 and 80 years old, of any sex.
- Your tumor must be located more than 10 cm from the anus (high enough to be treated before surgery).
- You must be able to perform daily activities (like walking or light housework) without help.
- Your blood, liver, kidney, and clotting tests must be within acceptable ranges.
- You must not have received any prior treatment for this colon cancer (such as surgery, chemotherapy, or radiation).
- You must not be pregnant or breastfeeding, and if you are male, you must agree to use reliable contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests two immunotherapy drugs given before surgery for colon cancer that has not spread. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study tests a new combination of medications for people with locally advanced colon cancer. It aims to see if adding tocilizumab to standard chemo-immunotherapy can help shrink or control the tumor.
This trial tests a new combination of drugs for advanced stomach cancer that has not been treated before. The goal is to see if adding a cholesterol-lowering drug to standard chemotherapy and immunotherapy can help shrink tumors and improve outcomes.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.